Publications [#273441] of Richard S. Keefe

Journal Articles

1. Rosenheck, R; Swartz, M; McEvoy, J; Stroup, TS; Davis, S; Keefe, RS; Hsiao, J; Lieberman, J (2007). Second-generation antipsychotics: reviewing the cost-effectiveness component of the CATIE trial.. Expert Rev Pharmacoecon Outcomes Res, 7(2), 103-111.
   (last updated on 2024/01/01)

   Abstract:
   The cost-effectiveness component of the 18-month CATIE trial of schizophrenia pharmacotherapy (n = 1460) showed that the first-generation antipsychotic perphenazine was US$300-600 per month less expensive than each of four second-generation antipsychotics, and no less effective across multiple measures. We consider whether or not each of eight potential methodological limitations could weaken this conclusion: follow-up rates, study duration, sample characteristics, the choice of outcome measures, exclusion of patients with tardive dyskinesia from assignment to perphenazine, choice of study drugs and doses, reliance on intention-to-treat analysis, and differences in prestudy treatment. We conclude that results of CATIE are robust to these limitations. Perphenazine seems to have been a more representative choice for first-generation antipsychotic comparison treatment than haloperidol.